Clearmind Medicine (CMND) vs GRI Bio (GRI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GRI Bio is the larger company by market cap ($3.8 million vs $3.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMND | GRI |
|---|---|---|
| Share price | $6.52 | $1.72 |
| Market cap | $3.31M | $3.76M |
| 1-day change | -1.24% | +2.38% |
| EPS (TTM) | $-461.20 | $-14.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3,840.00 | $64.12 |
| 52-week low | $5.25 | $1.36 |
| Distance from 52-week high | -99.83% | -97.32% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +975.58% |
| Average volume | 70.89K | 328.24K |
| Shares outstanding | 507.40K | 2.19M |
| Employees | — | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Clearmind Medicine
CMND stock →Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression.
Health Care · Biotechnology: Pharmaceutical Preparations
About GRI Bio
GRI stock →GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
CMND vs GRI FAQ
Which is bigger, Clearmind Medicine or GRI Bio?
GRI Bio (GRI) is larger, with a market capitalization of $3.76M compared with $3.31M for Clearmind Medicine (CMND).
Are Clearmind Medicine and GRI Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.